Arcus Biosciences Discontinues Lung Cancer Trial With Gilead
By Katherine Hamilton
Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences.
Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn't expect the trial to yield positive results. It also ended a phase 2 study.
Gilead's option rights to certain early pipeline programs under its 2020 agreement with Arcus will end in July due to Gilead's decision to not make the option continuation payment to Arcus.
Gilead won't have option rights to additional Arcus programs, but will maintain its existing time-limited options.
The decision is based on the recommendation of the Independent Data Monitoring Committee, following its review of data from a pre-planned futility analysis.
The analysis didn't assess safety, but no new safety issues were identified during regular reviews.
Gilead is communicating with investigators to determine appropriate next steps for patients in the studies.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
April 20, 2026 09:02 ET (13:02 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The Top Funds for a Simpler Retirement Portfolio
The 10 Best Dividend Stocks
United States